Key result
Review of previous clinical trials in heart failure with reduced ejection fraction reveals markers that can support clinical Go/NoGo decisions in early drug development.
Discusses the need for surrogate markers and trial endpoints other than mortality to guide early drug development decisions in heart failure with reduced ejection fraction.
There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.
No takes yet. Share an insight, caveat, or question.
Hinder et al. (2018) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Review of previous clinical trials in heart failure with reduced ejection fraction reveals markers that can support clinical Go/NoGo decisions in early drug development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: